Answers are grounded in this paper and cite their sources.
Vascular access for hemodialysis remains a challenge for end stage renal failure (ESRF) patients. Autogenous arterio-venous fistulae are the first choice, but synthetic grafts may be required. The Spiral FlowTM graft (SF) mimics physiological blood flow to minimize turbulence and neointimal hyperplasia. We analyzed patency of SF for hemodialysis at a vascular unit in Johannesburg, South Africa. A retrospective review was performed of upper arm SF implanted between 2013-2015. Primary and secondary patency rates were analyzed. Eighty grafts were placed in 71 patients. The primary and secondary patency rates at 1 year were 54% (95% CI: 41%-65%) and 63% (95% CI: 43%-78%), respectively. Poor patency risks such as Black ethnicity, hypertension, diabetes and HIV, were present in 75%, 61%, 26% and 19%, respectively. SFs were associated with acceptable patency rates in ESRF patients. Excessive comorbidities may affect patency rates.
No takes yet. Share an insight, caveat, or question.
Mistry et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: